Holen Sie sich die Stockscreener-App
9.05
0.98%
-0.09
Handel nachbörslich:
8.94
-0.11
-1.22%
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 earnings call transcript - MSN
Kura Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Lake Street initiates coverage of Kura Oncology (KURA) with buy recommendation - MSN
KURA Initiates Coverage On Lake Street -- Price Target Announced at $23 - GuruFocus
Aug Drivers: What are the future prospects of Kura Oncology IncMarket Growth Report & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
[ARS] Kura Oncology, Inc. SEC Filing - Stock Titan
Kura Oncology (NASDAQ: KURA) plans votes on pay, equity plan and auditor - Stock Titan
Bond Watch: Why is Kura Oncology Inc stock going up2026 Market Mood & Risk Managed Investment Signals - baoquankhu1.vn
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura to unveil new kidney cancer combo data in previously treated patients - Stock Titan
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 - Bitget
Breakout Move: Is Kura Oncology Inc vulnerable to short sellers2026 Market Sentiment & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule - National Today
Kura Oncology Grants Inducement Stock Options to New Employees as Part of 2023 Inducement Option Plan - Quiver Quantitative
Cancer drugmaker Kura gives 6 new hires options on 153,750 shares - Stock Titan
Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Kura Oncology: Commercialization In AML Presents Asymmetric Upside (NASDAQ:KURA) - Seeking Alpha
Vanguard reports 0% ownership in Kura Oncology (NASDAQ: KURA) - Stock Titan
Kura Oncology Inc (HAM:KUR) Stock Price, Trades & News - GuruFocus
Kura Oncology (NASDAQ: KURA) CEO exercises options, increases share stake - Stock Titan
Mizuho Cuts Price Target on Kura Oncology to $25 From $30, Keeps Outperform Rating - marketscreener.com
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Mizuho Cuts Kura Oncology (NASDAQ:KURA) Price Target to $25.00 - MarketBeat
Mizuho cuts Kura Oncology stock price target on delayed sales By Investing.com - Investing.com Canada
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Kura Oncology Inc stock surges on positive mid-stage trial results for key cancer drug candidate - AD HOC NEWS
KURA SEC FilingsKura Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Is Kura Oncology Inc a strong candidate for buy and holdMarket Sentiment Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
Kura Oncology (KURA) director exercises 10,000 options for shares - Stock Titan
Kura Oncology Inc Stock (ISIN: US50126D1028) Faces Post-Earnings Pressure Amid Komzifti Launch Chall - AD HOC NEWS
Kura Oncology anticipates $7B AML opportunity as KOMZIFTI launches and combination strategies advance - MSN
UBS Maintains Buy on KURA (Kura Oncology) March 2026, PT $15 - Meyka
Prosight Management LP Sells 422,668 Shares of Kura Oncology, Inc. $KURA - MarketBeat
KURA: UBS Analyst Maintains 'Buy' Rating But Lowers Price Target | KURA Stock News - GuruFocus
UBS lowers Kura Oncology stock price target to $15 on launch data - Investing.com Canada
Implied volatility surging for Kura Oncology stock options - MSN
Implied Volatility Soars for Kura Oncology Option Contracts - Bitget
Kura Oncology at Barclays Conference: Strategic Focus on Drug Combinations - Investing.com Canada
Implied Volatility Surging for Kura Oncology Stock Options - TradingView
KURA: Komzifti and ziftomenib advance with strong launch, global trials, and promising pipeline updates - TradingView — Track All Markets
(KURA) Risk Channels and Responsive Allocation - Stock Traders Daily
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates - Investing.com Nigeria
Kura Oncology at Leerink Global Healthcare Conference: Strategic Expansion Insights - Investing.com Canada
KURA: Rapid market access and robust pipeline drive growth and leadership ambitions in precision oncology - TradingView
KURA: Multiple clinical readouts and strong commercial momentum position for leadership in targeted oncology - TradingView
FY2027 EPS Forecast for Kura Oncology Lowered by Analyst - MarketBeat
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets - Yahoo Finance
UBS Reaffirms Their Buy Rating on Kura Oncology (KURA) - The Globe and Mail
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology 2025 Financials: Q4 Loss Widens, Misses Analyst EstimatesNews and Statistics - IndexBox
Kura Oncology Q4 2025 earnings preview - MSN
Kura Oncology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KURA) 2026-03-06 - Seeking Alpha
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):